Oxidative stress and anti-oxidative defence in patients with age-related macular degeneration

Current Eye Research

Volumn 38, Issue 4, 2013, Pages 497-502

  Uǧurlu, Nagihan ^a   Aşik, Mehmet Doǧan ^b   Yülek, Fatma ^a   Neselioglu, Salim ^a   Cagil, Nurullah ^a  

^a YILDIRIM BEYAZIT UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Age related macular degeneration; Anti oxidative defence; Oxidative stress; ROS; TTS

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; THIOL;

ADULT; ANTIOXIDANT ACTIVITY; ANTIOXIDANT ASSAY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; FEMALE; HUMAN; MALE; MIDDLE AGED; OXIDATIVE STRESS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION;

ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; OXIDANTS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SULFHYDRYL COMPOUNDS;

EID: 84890697949     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2013.774023     Document Type: Article

References (50)

1. Casten R, Rovner B, Tasman W. Age-related macular degeneration and depression: a review of recent research. Curr Opin Ophthalmol 2004;15:181-183.
2. Vingerling JR, Klaver CC, Hofman A, De Jong PT. Epidemiology of age-related maculopathy. Epidemiol Rev 1995;17:347-359.
3. Verma L, Das T, Binder S, Heriot WJ, Kirchhof B, Venkatesh P, et al. New approaches in the management of choroidal neovascular membrane in age related macular degeneration. Indian J Ophthalmol 2000;48:263-278.
4. World Health Organization. Vision 2020. Global initiative for the elimination of avoidable blindness. Action Plan 2006-2011. Available from: http://www.who.int/blindness/Vision2020% 20-report.pdf (last accessed 23 Sep. 2011].
5. Smiddy WE. Economic implications of current age-related macular degeneration treatments. Ophthalmology 2009;116:481-487.
6. MacDonald IM. Genetic aspects of age-related macular degeneration. Can J Ophthalmol 2005;40:288-292.
7. Anand R, Bressler SB, Davis MD, Ferris FL, Klein R, Cindblad AS, et al. Age related eye disease study research group: risk factors associated with age related macular degeneration. A case control study in the age related eye disease study: age related eye disease study report number 3. Ophthalmology 2000;107:2224-2232.
8. Suzuki M, Kamei M, Itabe H, Yoneda K, Bando H, Kume N, et al. Oxidized phospholipids in the macula increase with age and in eyes with age-related macular degeneration. Mol Vis 2007;13:772-778.
9. Halliwell B, Gutteridge J M C. Free radicals in biology and medicine. 4th ed. Oxford: Oxford University Press; 2006.
10. Cai J, Nelson KC, Wu M, Sternberg Jr P, Jones DP. Oxidative damage and protection of the RPE. Prog Retin Eye Res 2000;19:205-221.
11. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005;38:1103-1111.
12. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 2004;37:277-285.
13. Young IS, Woodside JV. Antioxidants in health and disease. J Clin Pathol 2001;54:176-186.
14. Wlodek L. Beneficial and harmful effects of thiols. Pol J Pharmacol 2002;54:215-223.
15. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004;37:112-119.
16. Andersson A, Lindgren A, Arnadottir M, Prytz H, Hultberg B. Thiols as a measure of plasma redox status in healthy subjects and in patients with renal or liver failure. Clin Chem 1999;45:1084-1086.
17. Maxwell S R J. Coronary artery disease-free radical damage, antioxidant protection and the role of homocysteine. Basic Res Cardiol 2000;95:65-71.
18. Javadzadeh A, Ghorbanihaghjo A, Bahreini E, Rashtchizadeh N, Argani H, Alizadeh S. Plasma oxidized LDL and thiol-containing molecules in patients with exudative age-related macular degeneration. Mol Vis 2010;16:2578-2584.
19. Coral K, Raman R, Rathi S, Rajesh M, Sulochana KN, Angayarkanni N, et al. Plasma homocyctein and total thiol contend in patients with exudative age related macular degeneration. Eye 2006;20:203-207.
20. Thiersch M, Raffelsberger W, Frigg R, Samardzija M, Wenzel A, Poch O, et al. Analysis of the retinal gene expression profile after hypoxic preconditioning identifies candidate genes for neuroprotection. BMC Genomics 2008;9:73.
21. Ng CJ, Shih DM, Hama SY, Villa N, Navab M, Reddy ST. The paraoxonase gene family and atherosclerosis. Free Radic Biol Med 2005;38:153-163.
22. Aviram M. Atherosclerosis: cell biology and lipoproteins - inflammation and oxidative stress in atherogenesis: protective role for paraoxonases. Curr Opinion in Lipidol 2011;22:243-244.
23. Aviram M, Rosenblat M. Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr Opin Lipidol 2005;16:393-399.
24. Dantoine TF, Debord J, Charmes JP, Merle L, Marquet P, Lachatre G, et al. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 1998;9:2082-2088.
25. Quemeneur T, Martin-Nizard F, Kandoussi A, Kyndt X, Vanhille P, Hachulla E, et al. PON1, a new biomarker of cardiovascular disease, is low in patients with systemic vasculitis. Semin Arthritis Rheum 2007;37:149-155.
26. Boemi M, Leviev I, Sirolla C, Pieri C, Marra M, James RW, et al. Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives: influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis 2001;155:229-235.
27. Baskol G, Karakucuk S, Oner AO, Baskol M, Kocer D, Mirza E, et al. Serum paraoxonase 1 activity and lipid peroxidation levels in patients with age-related macular degeneration. Ophthalmologica 2006;220:12-16.
28. Ates O, Azizi S, Alp HH, Kiziltunc A, Beydemir S, Cinici E, et al. Decreased serum paraoxonase 1 activity and increased serum homocysteine and malondialdehyde levels in age-related macular degeneration. Tohoku J Exp Med 2009;217:17-22.
29. Javadzadeh A, Ghorbanihaghjo A, Bahreini E, Rashtchizadeh N, Argani H, Alizadeh S. Serum paraoxonase phenotype distribution in exudative age-related macular degeneration and its relationship to homocysteine and oxidized low-density lipoprotein. Retina 2012;32:658-666.
30. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983;35:1126-1138.
31. Hu ML, Louie S, Cross CE, Motchnik P, Halliwell B. Antioxidant protection against hydrochlorous acid in human plasma. J Lab Clin Med 1993;12:257-262.
32. Da Costa CM, Dos Santos CC, Emerson S, Lima ES. A simple automated procedure for thiol measurement in human serum samples. J Bras Patol Med Lab 2006;42:345-350.
33. Antonio Trujillo-Ortiz. 2005. Available from: http://www.mafhworks.com/ matlabcentral/fileexchange/2844-hotellingt2 [last accessed 14 May 2012].
34. Antonio Trujillo-Ortiz. 2007. Available from: http://www.mathworks.com/ matlabcentral/fileexchange/3519 [last accessed 14 May 2012].
35. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000;45:115-134.
36. Winkler BS, Boulton ME, Gottsch JD, Sternberg P. Oxidative damage and age-related macular degeneration. Mol Vis 1999;5:32-33.
37. Handa JT, Verzijl N, Matsunaga H, Aotaki-Keen A, Lutty GA, Te Koppele JM, et al. Increase in the advanced glycation end product pentosidine in Bruch's membrane with age. Invest Ophthalmol Vis Sci 1999;40:775-779.
38. Ohia SE, Opere CA, Leday AM. Pharmacological consequences of oxidative stress in ocular tissues. Mutat Res 2005;579:22-46.
39. Bailey TA, Kanuga N, Romero IA, Greenwood J, Luthert PJ, Cheetham ME. Oxidative stress affects the junctional integrity of retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 2004;45:675-684.
40. Gottsch JD, Pou S, Bynoe LA, Romen GM. Hematogenous photosensitization: a mechanism for the development of age-related macular degeneration. Invest Ophahalmol Vis Sci 1990;31:1674-1682.
41. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004;122:598-614.
42. Snodderly DM. Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins. Am J Clin Nutr 1995;62:1448S-1461S.
43. Delcourt C, Cristol JP, Leger CL, Descomps B, Papoz L. Associations of antioxidant enzymes with cataract and age-related macular degeneration. The POLA Study. Ophthalmology 1999;106:215-222.
44. Sen CK. Cellular thiols and redox-regulated signal transduction. Curr Top Cell Regul 2000;36:1-30.
45. Pauer GJ, Sturgill GM, Peachey NS, Hagstrom SA; Clinical Genomic and Proteomic AMD Study Group. Protective effect of paraoxonase 1 gene variant Glnl92Arg in agerelated macular degeneration. Am J Ophthalmol 2010;149:513-522.
46. Brion M, Sanchez-Salorio M, Corton M, De La Fuente M, Pazos B, Othman M, et al. Spanish multi-centre group of AMD. Genetic association study of age-related macular degeneration in the Spanish population. Acta Ophthalmol 2011;89:e12-e22. doi: 10.1111/j.l755-3768.2010.02040.x.
47. Jaouad L, De Guise C, Berrougui H, Cloutier M, Isabelle M, Fulop T, et al. Age-related decrease in high-density lipoproteins antioxidant activity is due to an alteration in the PONl's free sulfhydryl groups. Atherosclerosis 2006;185:191-200.
48. Ferretti G, Bacchetti T, Masciangelo S, Pallotta G. Lipid peroxidation in hemodialysis patients: effect of vitamin C supplementation. Clin Biochem 2008;41:381-386.
49. Kamei M, Yoneda K, Kume N, Suzuki M, Itabe H, Matsuda K, et al. Scavenger receptors for oxidized lipoprotein in age-related macular degeneration. Invest Ophthalmol Vis Sci 2007;48:1801-1807.
50. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999;26:892-904.